363 related articles for article (PubMed ID: 35524200)
1. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
Mital S; Nguyen HV
BMC Cancer; 2022 May; 22(1):501. PubMed ID: 35524200
[TBL] [Abstract][Full Text] [Related]
2. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
Schousboe JT; Kerlikowske K; Loh A; Cummings SR
Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.
Shih YT; Dong W; Xu Y; Etzioni R; Shen Y
Ann Intern Med; 2021 May; 174(5):602-612. PubMed ID: 33556275
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
Wong JZY; Chai JH; Yeoh YS; Mohamed Riza NK; Liu J; Teo YY; Wee HL; Hartman M
BMC Health Serv Res; 2021 Apr; 21(1):379. PubMed ID: 33892705
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
8. Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
van den Broek JJ; Schechter CB; van Ravesteyn NT; Janssens ACJW; Wolfson MC; Trentham-Dietz A; Simard J; Easton DF; Mandelblatt JS; Kraft P; de Koning HJ
J Natl Cancer Inst; 2021 Apr; 113(4):434-442. PubMed ID: 32853342
[TBL] [Abstract][Full Text] [Related]
9. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
10. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
[TBL] [Abstract][Full Text] [Related]
16. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
